share_log

BMO Capital Initiates Coverage On Prime Medicine With Outperform Rating, Announces Price Target of $19

BMO Capital Initiates Coverage On Prime Medicine With Outperform Rating, Announces Price Target of $19

BMO Capital以跑赢大盘的评级开始对Prime Medicine进行保险,宣布目标股价为19美元
Benzinga ·  2023/10/09 07:09

BMO Capital analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $19.

BMO Capital分析师Kostas Biliouris以跑赢大盘的评级开始对Prime Medicine(纳斯达克股票代码:PRME)进行报道,并宣布目标股价为19美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发